Browse Category

ASX:BRV News 18 August 2025

Espresso Machine Showdown 2025: Oracle Jet vs Sage Dual Boiler vs La Marzocco Linea Micra – Which Brews the Best?

Espresso Machine Showdown 2025: Oracle Jet vs Sage Dual Boiler vs La Marzocco Linea Micra – Which Brews the Best?

The Oracle Jet, launched in 2024, is Breville/Sage’s flagship 58 mm portafilter hybrid with a built-in grinder and Auto MilQ milk system. It uses two ThermoJet heating elements instead of traditional boilers, delivering near-instant heat-up and requiring a brief warm-up flush for stable first shots. The Breville/Sage Dual Boiler BES920 features two stainless steel boilers (brew and steam), a PID-controlled brew boiler with heated group head, and a 58 mm portafilter, priced around $1,500. A CoffeeGeek editor called the Dual Boiler his ideal machine and noted it has logged roughly 5,700 shots over years with only minor maintenance. La Marzocco
18 August 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop